Compare · ABSI vs PRAH
ABSI vs PRAH
Side-by-side comparison of Absci Corporation (ABSI) and PRA Health Sciences, Inc. (PRAH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and PRAH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI carries a market cap of $1.52B.
- ABSI has hit the wire 5 times in the past 4 weeks while PRAH has been quiet.
- ABSI has more recent analyst coverage (21 ratings vs 0 for PRAH).
- Company
- Absci Corporation
- PRA Health Sciences, Inc.
- Price
- $8.25-7.09%
- $165.29-1.68%
- Market cap
- $1.52B
- -
- 1M return
- -10.86%
- -
- 1Y return
- +71.52%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 5
- 0
- Recent ratings
- 21
- 0
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 2% to 483,144 units (SEC Form 4) (withholding obligation)
- Absci to Participate in Upcoming Investor Conferences
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
Latest PRAH
- Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
- SEC Form SC 13G filed by PRA Health Sciences, Inc.
- SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)
- SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Young Matthew P. returned 7,127 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Stettin Glen D. returned 1,049 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: MOMTAZEE JAMES C returned 3,521 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Dickinson Alexander George returned 5,407 units of Common Stock to the company, closing all direct ownership in the company